BRCA Complete™ Expanded Panel (For Illumina® Platforms)

Cat Number: BRCAX-NGS

The BRCA Complete™ Expanded Panel is a next-generation sequencing (NGS) assay that enables comprehensive detection of mutations in BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53 genes, offering a powerful tool for hereditary cancer risk assessment and guiding personalized treatment decisions, including PARP inhibitor therapy.

Analytical sensitivity as low as 5% MAF
Includes reagents for target enrichment; library preparation, clean up, sample and library QC
Compatible with Illumina® NextSeq 500, MiniSeq, and MiSeq sequencers
Complimentary data-analysis software for local installation available
40 tests per kit
For research use (RUO) in the U.S
For in vitro diagnostic use (IVD) in the European Union

Category: Breast/Ovarian Cancer Tag: BRCA

Request More Information

The BRCA Complete™ Expanded Panel is a next-generation sequencing (NGS) assay designed to detect clinically relevant germline mutations associated with hereditary cancer risk. The panel targets full exonic regions of six key genes: BRCA1, BRCA2, CHEK2, PALB2, RAD51C, and TP53—genes with well-documented associations to breast, ovarian, prostate, and other cancers.

The BRCA Complete™ Expanded Panel utilizes a highly multiplexed, tiled amplicon-based enrichment strategy to capture target regions with precision and efficiency. The assay covers 286 amplicons with an average size of 153 base pairs, ensuring comprehensive sequencing coverage across the targeted exons. Integrated indexing (500 and 700 series) and adapter ligation steps prepare enriched libraries for sequencing on Illumina® platforms.

The kit includes reagents for target enrichment and library construction. The panel is optimized for efficient processing and reliable variant detection, including SNVs, indels, and large rearrangements.

For laboratories seeking a streamlined and validated solution for hereditary cancer analysis, the BRCA Complete™ Expanded Panel provides robust performance and actionable insights.

Additionally, the POLE add on is available to be purchased separately for detection of mutation in POLE exons 9-14.

The BRCA Complete™ Expanded Panel offers a comprehensive and efficient next-generation sequencing (NGS) workflow for the detection of clinically relevant variants in hereditary cancer-associated genes. The assay is compatible with DNA extracted from blood, fresh frozen, and high-quality FFPE tissue samples, and is designed for use on Illumina® sequencing platforms. Genomic DNA from FFPE tissues can be extracted using EntroGen pureNA® Genomic DNA Isolation Kit.

This test includes reagents necessary for target enrichment, library preparation, and validated internal controls. The workflow incorporates DNA quantification, multiplex PCR-based target enrichment, and adaptor ligation, followed by purification and NGS-ready library generation.

Columns and reagents for DNA isolation are not included. DNA quantification using a qPCR-based assay is strongly recommended to ensure accurate input and optimal assay performance.

The following suplimentary products are recommended, but not supplied: